| Sign In to gain access to subscriptions and/or personal tools. |
The role of CD40 ligand in systemic lupus erythematosusDivision of Rheumatology, University of California San Francisco, San Francisco, USA
Division of Rheumatology, University of California San Francisco, San Francisco, USA, jdavis{at}medicine.ucsf.edu CD40 ligand (CD40L, also known as CD154 or gp39) is a member of the tumor necrosis superfamily of transmembrane proteins. The interaction of CD40L on activated T cells with its receptor, CD40 on B cells, is necessary for normal immune function, including B cell differentiation, germinal center formation, and antibody isotype switching. Abnormal expressionof CD40L in patients with systemic lupus erythematosus (SLE) may contribute to autoantibody production and disease pathogenesis. Although murine models of monoclonal antibodies directed against CD40L initially showed promise, human trials either have failed to demonstrate efficacy or have been associated with adverse events. This review will summarize in vitro and murine model data and human clinical trials involving anti-CD40L monoclonal antibody.
Key Words: CD 154 • CD40 ligand • gp 39 • review • systemic lupus erythematosus
Lupus, Vol. 13, No. 5,
377-380 (2004) This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
